The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer
Open accessAbstract
Several phosphoinositide 3-kinase (PI3K) catalytic subunit inhibitors are currently in clinical trial. We therefore sought to examine relationships between pharmacologic inhibition and somatic mutations in PI3K catalytic subunits in estrogen receptor (ER)–positive breast cancer, in which these mutations are particularly common. RNA interference (RNAi) was used to determine the effect of selective inhibition of PI3K catalytic subunits, p110α and p110β, in ER+ breast cancer cells harboring either mutation (PIK3CA) or gene amplification (PIK3CB). p110α RNAi inhibited growth and promoted apoptosis in all tested ER+ breast cancer cells under estrogen deprived-conditions, whereas p110β RNAi only affected cells harboring PIK3CB amplification. Moreover, dual p110α/p110β inhibition potentiated these effects. In addition, treatment with the clinical-grade PI3K catalytic subunit inhibitor BEZ235 also promoted apoptosis in ER+ breast cancer cells. Importantly, estradiol suppressed apoptosis induced by both gene knockdowns and BEZ235 treatment. Our results suggest that PI3K inhibitors should target both p110α and p110β catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER+ breast cancer. [Cancer Res 2009;69(9):3955–62]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Cited by
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Luminal breast cancer: from biology to treatment
Ignatiadis, M., & Sotiriou, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.124 · Cited by 469
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, A., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 417
Metadata
- Authors
- Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., Snider, J., Davies, S. R., Olson, J. A., Watson, M. A., Saporita, A., Weber, J. D., & Ellis, M. J.
- Venue
- Cancer Research
- Published
- 2009-04-30
- Volume
- 69
- Issue
- 9
- Pages
- 3955-3962
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2162003888
- Cited by
- 218
- References
- 2
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-4450
- The paper
- Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., Snider, J., Davies, S. R., Olson, J. A., Watson, M. A., Saporita, A., Weber, J. D., & Ellis, M. J. (2009). PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-4450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.